Δημοσίευση στις Jun 2019 στο PubMed: https://pubmed.ncbi.nlm.nih.gov/31054483/?from_term=tsioufis&from_sort=date&from_size=200&from_pos=36
Guy De Backer
, Piotr Jankowski
, Kornelia Kotseva
, Erkin Mirrakhimov
, Željko Reiner
, Lars Rydén
, Lale Tokgözoğlu
, David Wood
, Dirk De Bacquer
, EUROASPIRE V collaborators, Writing Committee, Scientific Steering/ Executive Committee, Coordinating centre, Diabetes centre, Data management centre, Statistical analysis centre, Central laboratory, Study centres, organisations, investigators and other research personnel (National Co-ordinators in each country are indicated by asterisk
Background and aims:
One of the objectives of the ESC-EORP EUROASPIRE V survey is to determine how well European guidelines on the management of dyslipidaemias are implemented in coronary patients.
Standardized methods were used by trained technicians to collect information on 7824 patients from 130 centers in 27 countries, from the medical records and at a visit at least 6 months after hospitalization for a coronary event. All lipid measurements were performed in one central laboratory. Patients were divided into three groups: on high-intensity LDL-C-lowering-drug therapy (LLT), on low or moderate-intensity LLT and on no LLT.
At the time of the visit, almost half of the patients were on a high-intensity LLT. Between hospital discharge and the visit, LLT had been reduced in intensity or interrupted in 20.8% of the patients and had been started or increased in intensity in 11.7%. In those who had interrupted LLT or had reduced the intensity, intolerance to LLT and the advice of their physician were reported as the reason why in 15.8 and 36.8% of the cases, respectively. LDL-C control was better in those on a high-intensity LLT compared to those on low or moderate intensity LLT. LDL-C control was better in men than women and in patients with self-reported diabetes.
The results of the EUROASPIRE V survey show that most coronary patients have a less than optimal management of LDL-C. More professional strategies are needed, aiming at lifestyle changes and LLT adapted to the need of the individual patient.
Coronary heart disease; Dyslipidaemia; EUROASPIRE; LDL-Cholesterol; Lipid lowering therapy; Secondary prevention.